5 Overstated
Approximately 115 million adults in the United States have pre-diabetes.
"Right now, about 115 million adults in the US have pre-diabetes. Most don't know it, and a higher percentage of men have it than women do." (said at 0:13:13)
The speaker correctly notes that most individuals with prediabetes are unaware of their condition (CDC surveillance shows awareness has historically been ~11-19%) and that prevalence is higher among men than women. However, the stated figure of 115 million adults with prediabetes is overstated. According to the CDC's National Diabetes Statistics Reports and NHANES epidemiological surveillance data, approximately 96 to 98 million U.S. adults (about 38% of the adult population, up from 84 million in 2016 and 79 million in 2010) have prediabetes, overshooting actual estimates by roughly 17 to 20 million.
Pinealon modulates expression of genes and pathways including GDF11, SOD1, SOD2, irisin, PPAR-alpha, and PPAR-gamma.
"So Pinealon in one sentence: it's leading to better brain metabolism through modulating all these different pathways, for example GDF11, SOD1, SOD2, irisin, PPAR-alpha, PPAR-gamma." (said at 1:14:12)
While narrative and in vitro research on the synthetic tripeptide Pinealon (Glu-Asp-Arg / EDR) describes potential effects on antioxidant enzymes (such as SOD2) and transcription factors including PPARA (PPAR-alpha) and PPARG (PPAR-gamma), there is no published evidence demonstrating that Pinealon modulates GDF11 or irisin. Grouping unverified targets like GDF11 and irisin alongside preliminary in vitro findings overstates the established biological pathways modulated by Pinealon.
- partial: EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involv… (Molecules (Basel, Switzerland) 2020) · cited 13x in the literature
"Thus, the EDR peptide can change the activity of the MAPK/ERK signaling pathway, the synthesis of proapoptotic proteins (caspase-3, p53), proteins of the antioxidant system (SOD2, GPX1), transcription factors PPARA, PPARG, serotonin, calmodulin." (abstract, results, passage verified)
pubmedfull study (doi)
Topical GHK-Cu has human clinical data demonstrating positive aesthetic outcomes and alleviation of UV photodamage.
"topically, there's great human data on different aesthetic outcomes, especially when coupled with red light therapy... There's also some literature when it comes to GHK-Cu for post-UV damage." (said at 2:16:58)
The claim that there is 'great human data' on topical GHK-Cu for aesthetic outcomes and UV damage is overstated. While preclinical, in vitro, and animal models demonstrate that GHK-Cu stimulates collagen and glycosaminoglycan synthesis, modulates matrix metalloproteinases, and reduces inflammation, rigorous human clinical evidence remains scarce. A 2026 PRISMA-guided systematic review of GHK-Cu in aesthetic medicine identified 20 relevant studies, of which 18 were preclinical and only 2 were randomized controlled trials, concluding that clinical utility is constrained by methodological variability and a limited number of well-designed trials. Another 2025 review noted a surprising absence of robust clinical trials despite the compound's widespread commercial use.
- contradicts: Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. (BioImpacts : BI 2025) · cited 6x in the literature
"Although GHK-Cu and Pal-GHK have been of interest as effective peptides to be incorporated in the anti-wrinkle products, there is a surprising absence of clinical studies using them." (abstract, conclusions, passage verified)
pubmedfull study (doi) - partial: The Regenerative Potential of GHK-Cu in Aesthetic Medicine. (Aesthetic surgery journal 2026)
"20 studies (18 preclinical; 2 RCTs) were included. Preclinical data consistently demonstrated that GHK-Cu enhances extracellular matrix synthesis (type I collagen and glycosaminoglycans), modulates metalloproteinase activity, and promotes angiogenesis and cellular proliferation... Clinically, GHK-Cu improved patient-reported satisfaction after laser resurfacing and significantly reduced wrinkle volume and depth compared with controls... Nevertheless, the findings reported across studies were constrained by methodological variability and a limited number of well-designed clinical trials." (abstract, results and conclusions, passage verified)
pubmedfull study (doi)
Models and cohorts with growth hormone deficiency exhibit extended lifespan.
"There's models where people are growth hormone deficient and they live a lot longer" (said at 2:08:15)
Genetic animal models with growth hormone (GH) deficiency or GH receptor knockouts (such as Ames dwarf, Snell dwarf, and GHR-/- mice) reliably exhibit significantly extended lifespans (often 30–50% longer). However, in human cohorts with congenital isolated GH deficiency or GH resistance (e.g., Laron syndrome, PROP1 mutations on Krk island, or the Itabaianinha GHRH receptor cohort), individuals exhibit normal lifespans and protection against cancer and diabetes, but have not been demonstrated to live significantly longer than their unaffected relatives or normal controls.
- context: Effects of growth hormone and insulin-like growth factor 1 deficiency on ageing and longev… (Novartis Foundation symposium 2002) · cited 44x in the literature
"In conclusion longstanding GH/IGF1 deficiency affects several parameters of the ageing process without impairing lifespan, and as shown in animal models prolongs longevity." (abstract, conclusions, passage verified)
pubmed - context: Do deficiencies in growth hormone and insulin-like growth factor-1 (IGF-1) shorten or prol… (Mechanisms of ageing and development 2005) · cited 122x in the literature
"Studying untreated patients with either isolated GH deficiency due to GH gene deletion, patients with multiple pituitary hormone deficiency due to PROP-1 gene mutation and patients with isolated IGF-I deficiency due to deletions or mutations of the GH receptor gene (Laron syndrome); it was found, that these patients despite signs of early aging (wrinkled skin, obesity, insulin resistance and osteopenia) have a long life span reaching ages of 80-90 years. Animal models of genetic GH deficiencies such as Snell mice (Pit-1 gene mutations) the Ames mice (PROP-1 gene mutation) and the Laron mice (GH receptor gene knock-out) have a statistically significant higher longevity compared to normal controls." (abstract, results, passage verified)
pubmedfull study (doi) - context: Growth Hormone Deficiency: Health and Longevity. (Endocrine reviews 2019) · cited 201x in the literature
"Mice with isolated GHD (IGHD) due to GHRH or GHRH receptor mutations, combined deficiency of GH, prolactin, and TSH, or global deletion of GH receptors live longer than do their normal siblings... We think that low, but detectable, residual GH secretion combined with life-long reduction of circulating IGF-1 and with some tissue levels of IGF-1 and/or IGF-2 preserved may account for the normal longevity and apparent extension of healthspan in these individuals." (abstract, results)
pubmedfull study (doi)
In mouse studies, BPC-157 prevents mice from getting hyperactive or experiencing withdrawal from methamphetamines.
"They can't get too high on the mice methamphetamines, and they don't withdraw either." (said at 2:40:56)
The claim is overstated. Preclinical rodent studies (predominantly from one research group) found that BPC-157 attenuated acute amphetamine-induced stereotypy and heightened acoustic startle responses in rats, reversed haloperidol-induced supersensitivity to amphetamine in mice, and reduced chronic amphetamine-induced behavioral disturbances. However, these studies evaluated motor stereotypies and behavioral sensitization rather than demonstrating that mice do not experience subjective intoxication ('cannot get too high') or clinical methamphetamine withdrawal. The evidence is preliminary and restricted to animal models.
- partial: Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances. (Acta pharmacologica Sinica 2002) · cited 28x in the literature
"In summary, gastric pentadecapeptide BPC 157 (ie, both microg- and ng-BPC 157 regimens) attenuated chronic amphetamine disturbances. This effect was present throughout the observation period at a statistically significant level. Therefore, it seems that this gastric pentadecapeptide BPC 157 has a modulatory effect on dopamine system, and it could be used in chronic amphetamine disturbances." (abstract, results, passage verified)
pubmed - partial: A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine a… (Biological psychiatry 1998) · cited 46x in the literature
"There was a marked attenuation of stereotypic behavior and acoustic startle response. When the medication was given at the time of maximum amphetamine-induced excitability, there was a reversal of this behavior. A further focus was on the effect of this pentadecapeptide on increased climbing behavior in mice pretreated with the dopamine antagonist haloperidol (5.0 mg/kg i.p.), and subsequently treated with amphetamine (20 mg/kg i.p. challenge 1, 2, 4, and 10 days after haloperidol pretreatment)... An almost complete reversal was noted when pentadecapeptide was coadministered with haloperidol." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.